Abstract-␣-Adrenergic receptor (AR) activation enhances sodium retention in certain forms of hypertension. The objective of the present study was to understand the role of ␣-ARs in regulating sodium transport by distal tubules (DT). DT cells were isolated from kidneys of spontaneously hypertensive rats (SHR) and Wistar-Kyoto (WKY) rats at 6 weeks, when hypertension is developing, or at 12 weeks, when hypertension is established. The ␣ 1 -AR agonist phenylephrine increased 22 Na uptake by 50% into DT cells of 6-week SHR; no effect was observed with WKY cells. The ␣ 2 -AR agonist B-HT 933 increased uptake by only 10%. At 12 weeks, the pattern of ␣-AR regulation was reversed: ␣ 1 -AR-induced sodium uptake was only 15%, whereas ␣ 2 -AR activation increased sodium uptake by 35% in SHR and WKY cells. ␣ 1 -AR-induced sodium uptake in 6-week SHR cells was abolished by prazosin; ␣ 2 -AR-stimulated sodium uptake was blocked by yohimbine in 12-week SHR and WKY. Key Words: receptors, adrenergic Ⅲ blood pressure Ⅲ catecholamines Ⅲ epinephrine Ⅲ hypertension Ⅲ calcium Ⅲ norepinephrine O ne proposal for the initiation and maintenance of hypertension centers on a reduced capacity of the kidneys to excrete salt and water in proper relation to intake. 1 Sodium retention could initiate or contribute to the development of hypertension by activating mechanisms in vascular smooth muscle, the sympathetic nervous system, or expansion of effective extracellular fluid or plasma volume. 2,3 Chronic stimulation of renal nerves or intrarenal infusion of norepinephrine increases sodium retention and is capable of producing hypertension. 4,5 Conversely, renal denervation attenuates sodium retention and the onset of hypertension 6,7 but exerts only minimal effects in adult animals with established hypertension. 7, 8 Metabolic balance studies examining the intake and excretion of sodium and water document that spontaneously hypertensive rats (SHR) between 4 to 7 weeks of age retain more sodium than do age-matched Wistar-Kyoto (WKY) rats. 2 During this period, urinary excretion was less in SHR than WKY rats and attributed to renal mechanisms. As the animals matured and systolic arterial pressure increased, renal sodium excretion was normalized in 8-to 13-week SHR. 9 These findings suggest that altered regulation of renal sodium absorption parallels the increase in pressure observed in SHR.
O ne proposal for the initiation and maintenance of hypertension centers on a reduced capacity of the kidneys to excrete salt and water in proper relation to intake. 1 Sodium retention could initiate or contribute to the development of hypertension by activating mechanisms in vascular smooth muscle, the sympathetic nervous system, or expansion of effective extracellular fluid or plasma volume. 2, 3 Chronic stimulation of renal nerves or intrarenal infusion of norepinephrine increases sodium retention and is capable of producing hypertension. 4, 5 Conversely, renal denervation attenuates sodium retention and the onset of hypertension 6, 7 but exerts only minimal effects in adult animals with established hypertension. 7, 8 Metabolic balance studies examining the intake and excretion of sodium and water document that spontaneously hypertensive rats (SHR) between 4 to 7 weeks of age retain more sodium than do age-matched Wistar-Kyoto (WKY) rats. 2 During this period, urinary excretion was less in SHR than WKY rats and attributed to renal mechanisms. As the animals matured and systolic arterial pressure increased, renal sodium excretion was normalized in 8-to 13-week SHR. 9 These findings suggest that altered regulation of renal sodium absorption parallels the increase in pressure observed in SHR.
The focus of this study was to test the hypothesis that ␣-adrenergic receptors (␣-ARs) contribute to the increased sodium absorption in distal tubule (DT) cells of SHR during developing hypertension (4 to 7 weeks). Renal nerves impinge directly on proximal tubules (PT) and DT. 10 Previous studies showed that ␣ 1 -and ␣ 2 -AR agonists stimulate Na ϩ /H ϩ exchange to a similar level in PT cells from SHR and WKY rats from 4 to 16 weeks of age. 11 It is predicted that ␣-ARs increase sodium absorption in DT cells. The mammalian DT is composed of 3 segments: distal convoluted tubule, connecting tubules, and initial cortical collecting duct. 12 In aggregate, these segments critically regulate the absorption of up to 15% of the filtered sodium load. 13 Activation of ␣-ARs on DT segments may significantly increase sodium retention during the developing phase of hypertension in SHR. The enhanced sodium retention observed during this phase may be due to increased expression of receptor subtypes or alternative receptor signaling.
It is proposed that a reversal of ␣ 1 -and ␣ 2 -AR regulation occurs during the developing and established hypertension. During the phase of increasing blood pressure in SHR, ␣ 1 -ARs increase sodium transport in DT cells. The increase in ␣ 1 -AR-stimulated sodium uptake correlates with increased ␣ 1B -AR binding on DT cells during developing hypertension. In established hypertension in SHR and in normotensive WKY rats, ␣ 2 -ARs, but not ␣ 1 -ARs, increase sodium transport. These observations indicate increases in specific ␣ 1 -AR subtypes enhance sodium transport in DT cells during developing hypertension and ␣ 2 -ARs regulate sodium absorption in DT cells during established hypertension and normotension.
Methods

Preparation of Freshly Isolated and Primary Cultures of Tubule Cells From SHR and WKY Rats
Salt-insensitive SHR and WKY rats of 6 and 12 weeks of age were obtained (Taconic) and maintained on normal rat chow and water ad libitum. The weights of 6-and 12-week-old SHR were similar to those of WKY rats. Systolic blood pressures were measured in awake animals as previously reported. 11 The blood pressures of 6-week-old SHR averaged 139 mm Hg compared with 106 mm Hg in 6-week-old WKY rats (PϽ0.05). Blood pressures of 12-week-old SHR averaged 175 mm Hg, significantly greater than those observed with WKY rats (110 mm Hg), and agree with our previous observations 11 and those of others 14, 15 that correspond to developing hypertension and established hypertension phases. DT and PT cells were prepared from age-matched SHR and WKY rats of 6 weeks (developing hypertension) and 12 weeks (established hypertension) 16 with isolation of DT cells using a doubleantibody isolation technique. 17 Primary cultures of DT and PT cells were prepared from freshly isolated cells. 18 
Isotopic Sodium Uptake Measurements
A rapid filtration technique described in previous reports 19 was used to measure uptake of 22 Na into DCT cells. Briefly, WKY and SHR cells were placed in a sodium-containing buffer, with or without ␣ 1 -or ␣ 2 -AR agonists or antagonists for 1 minute before the addition and vortexing of 1 aliquot of 22 Na (Amersham) to initiate isotope uptake. In all experiments reported, tracer uptake was terminated after 1 minute by the rapid addition of ice-cold isosmotic Li 2 SO 4 -HEPES rinse buffer and filtered onto Whatman GF/C filters using a Millipore 12-port manifold. Bars denote meanϮSEM for triplicate measurements of 4 independent experiments. Final concentrations of the ␣ 1 -AR agonist PHE, the ␣ 2 -AR agonist B-HT 933, or the nonselective agonist NE were 1 mol/L. *PϽ0.01 denotes significant differences between control rates of uptake and agonist-treated rates. Figure 2 . Stimulation of sodium uptake by the nonselective agonist NE (1 mol/L) in DT cells from 6-and 12-week SHR and WKY. Bars denote meanϮSEM for triplicate measurements of 4 independent experiments. Final concentrations of the ␣ 1 -AR antagonist prazosin and the ␣ 2 -AR antagonist yohimbine were 10 mol/L. *PϽ0.01 denotes significant differences between control rates of uptake and agonist-treated rates in the presence and absence of antagonists.
respectively. Concentrations ranging from 0.01 to 5 nmol/L labeled ligand with 100 g SHR and WKY cell membrane protein were used per reaction tube. Nonspecific binding was assessed with 10 mol/L phentolamine or yohimbine. 20 22 For determining the relative proportions of ␣ 2A -and ␣ 2B -ARs in SHR and WKY DT and PT cell membranes, oxymetazoline (␣ 2A selective) and ARC239 (␣ 2B selective) were used. 23 Binding constants (B max , K d ) were calculated using nonlinear regression analysis with Prism software (GraphPAD Software).
Measurement of [Ca 2؉ ] i
Intracellular fluorescence measurements of calcium were performed as previously described in detail. 24 Primary cultures of SHR and WKY DT and PT cells were grown to near-confluence on 25-mm glass coverslips and incubated for 60 minutes at 37°C with Fura-2 AM (10 Ϫ5 mol/L; Molecular Probes). Fluorescence excitation and emission intensity were measured with a Nikon Photoscan-2.
Materials and Preparation of Drug Solutions
␣-AR agonists and antagonists were prepared so that the molar concentration indicated in the text is the final concentration to which cells were exposed. Solutions containing drugs were prepared fresh daily. Rolipram was purchased from BIOMOL Research Laboratories; B-HT 933 was a gift from Boehringer-Ingelheim Pharmaceuticals. Other adrenergic agonists and antagonists were purchased from Research Biochemical International. 
Statistical Evaluation of Data
Results
␣-AR Effects on Sodium Uptake
The responses of DT cells to equimolar concentrations of the ␣ 1 -selective agonist phenylephrine (PHE), the ␣ 2 -selective agonist B-HT 933, and the endogenous mixed norepinephrine (NE) are depicted in Figure 1 . The basal (control) rates of uptake were similar among SHR and WKY rats at both 6-and 12-week time points. Only DT cells from 6-week SHR increased sodium uptake when treated with PHE. There was no effect when 6-week WKY DT cells were treated with PHE. By comparison, DT cells from 6-week SHR exhibited no response to the ␣ 2 -AR agonist B-HT 933. DT cells from 6-week WKY rats increase sodium uptake in response to the ␣ 2 -AR agonist. Both 12-week SHR and WKY DT cells treated with B-HT 933 exhibit significantly increased rates of sodium uptake. The mixed ␣ 1 -and ␣ 2 -AR agonist NE increases sodium uptake in DT cells from SHR and WKY; this presumably is due to the ␣ 1 -AR stimulation in SHR DT cells at 6 weeks and ␣ 2 -AR stimulation that occurs in WKY and 12-week SHR DT cells.
Specific ␣ 1 -and ␣ 2 -AR antagonism of the NE response in 6-and 12-week SHR DT cells provides further evidence of the shift from ␣ 1 -AR regulation during developing hypertension and ␣ 2 -AR regulation during established hypertension. As depicted in Figure 2 , NE-stimulated sodium uptake into 6-week SHR DT cells is abolished by pretreatment with prazosin, an ␣ 1 -AR antagonist. At 12 weeks, NE-stimulated sodium uptake into SHR DT cells is blocked by the ␣ 2 -AR antagonist yohimbine. When 6-and 12-week WKY DT cells were stimulated with NE, sodium uptake was blocked only by yohimbine. Pretreatment of 6-or 12-week WKY DT cells with prazosin had no demonstrable effect on NE-stimulated sodium uptake.
Expression of ␣-AR Subtype Protein in Developing and Established Hypertension
To discern the subtypes of ␣ 1 -and ␣ 2 -ARs expressed in SHR and WKY DT cells, receptor protein was measured using and WKY. Specific binding averaged 73% to 90% in all saturation binding experiments. The mean ␣ 1 -AR density in 6-week SHR DT membranes was 250Ϯ26 fmol/mg protein and was significantly greater than that of 6-week WKY DT membranes (84Ϯ11 fmol/mg protein). The ␣ 1 -AR density of 12-week SHR DT membranes was 113Ϯ16 fmol/mg protein and comparable to the value detected for 12-week WKY DT membranes (92Ϯ14 fmol/mg protein). As depicted in Figure  4 , there is significantly greater ␣ 1B -AR binding with 6-week SHR DT membranes than with those of 12-week SHR or WKY DT membranes. The significant increase in total ␣ 1 -AR density of a 6-week SHR DT membranes is in large part attributable to the increased expression of the ␣ 1B -AR subtype. Compared with expression of ␣ 1B -ARs in 12-week SHR and WKY DT cells, there is nearly 4-fold greater expression of this subtype in 6-week SHR DT cells. Expression of ␣ 1A -AR subtypes was comparable in SHR and WKY 6-and 12-week DT membranes. Although message for ␣ 1D -AR was detected by RT-PCR, competitive binding studies indicate Ͻ6% of the total binding in DT membranes from SHR and WKY rats was attributable to this particular subtype. Conflicting results relating to the expression of the ␣ 1D -AR subtype indicate the absence of this subtype in kidney cortex, 25, 26 whereas ␣ 1D -AR mRNA is present in DT cells; protein expression of this subtype is very low in DT cells.
To determine whether protein expression of ␣ 1 -ARs is increased in other tubule segments, we measured ␣ 1 -AR binding in PT membranes from 6-and 12-week SHR and WKY rats ( Figure 5 ). The increased expression of the ␣ 1B -AR subtype is specific for DT membranes from 6-week SHR. The ␣ 1B -and ␣ 1A -AR subtype expression is not increased in PT membranes from SHR or WKY membranes at 6 or 12 weeks. Again, consistent with other reports, 25,26 ␣ 1A -and ␣ 1B -AR subtypes comprise Ϸ50% each of the ␣ 1 -ARs expressed on the PT. Expression of the ␣ 1D -AR averaged Ͻ7% of the total ␣ 1 -AR binding in WKY and SHR PT membranes.
We theorized that with a reduction in ␣ 1 -AR expression at 12 weeks in SHR DT cells, there may be an accompanying increase in expression of a particular ␣ 2 -AR subtype. To test this theory, competitive binding studies were performed with DT membranes from SHR and WKY rats of 6 and 12 weeks and summarized in Figure 6 . Similar levels of ␣ 2 -AR binding were observed in DT and PT cell membranes from 6-and 12-week SHR and WKY. Total specific binding of ␣ 2 -ARs was 93 fmol/mg protein in membranes from 6-week SHR compared with 84 fmol/mg protein in WKY. ␣ 2A -AR binding was 61 versus 47 fmol/mg protein in SHR compared with WKY, whereas ␣ 2B -AR binding was 44 versus 36 fmol/mg protein in SHR compared with WKY. With membranes from 12-week SHR, total specific binding was 106 versus 97 fmol/mg protein in SHR compared with WKY, respectively. ␣ 2A -AR binding was 68 fmol/mg protein compared with 57 fmol/mg protein in WKY. ␣ 2B -AR binding was ϳ50 fmol/mg protein for both SHR and WKY with membrane from 12-week DT cells. An equal ratio of ␣ 2A /␣ 2B sites in PT and DT membranes from SHR and WKY was consistent with densities reported by others. 25, 26 Although 6-week SHR express significantly greater numbers of ␣ 1B -ARs during developing hypertension, the densities of ␣ 2 -ARs remain constant during developing and established hypertension.
Signaling of ␣ 1 -and ␣ 2 -ARs During Developing and Established Hypertension
The ␣ 1 -and ␣ 2 -ARs activate a number of signaling pathways, including phosphoinositide-sensitive phospholipase C (PI- 31 but couple to PI-PLC in DT cells. 24 To examine the signal pathways activated by ␣ 1 -and ␣ 2 -ARs during developing and established hypertension, we measured agonist-induced increases of [Ca 2ϩ ] i in DT cells of SHR and WKY rats with the fluorescent dye, Fura-2 AM. A representative experiment is depicted in Figure 6 . After measurement of resting levels of 
Discussion
The objective of this study was to determine the role of ␣-ARs in the development of hypertension. We propose that renal ␣ 1 -ARs are important in the initiation and development of hypertension because they significantly increase sodium absorption in the DT, a segment that critically regulates 10% to 15% of final sodium excretion. As hypertension progresses, ␣ 1 -AR expression is downregulated and ␣ 2 -ARs regulate sodium absorption in DT cells.
Renal nerve stimulation reduces sodium excretion. 5 This effect is abolished by ␣ 1 -AR antagonists. 32 In rats chronically treated with prazosin, an ␣ 2 -AR antagonist is required to fully abolish the increase in sodium retention. 32 These findings suggest both ␣ 1 -and ␣ 2 -AR receptors regulate sodium absorption. In PT cells, ␣ 1 -and ␣ 2 -ARs exert synergistic effects on Na ϩ /H ϩ exchange. 33 However, ␣ 1 -and ␣ 2 -AR-stimulated Na ϩ /H ϩ exchange is similar in WKY and SHR PT cells during developing and established hypertension. 11 These findings support the view that ␣-AR regulation of sodium absorption is not altered in PT cells during developing hypertension.
Numerous studies indicate ␣ 1 -ARs enhance sodium retention. 5, 34, 35 SHR excrete significantly less sodium during the onset of hypertension (weeks 4 to 7). 36 As hypertension progresses, the tendency to retain sodium is reversed until levels approximate those of normotensives during weeks 10 to 13. Our results with ␣-AR stimulation of sodium uptake are consistent with these observations.
We observe significant differences in ␣ 1 -and ␣ 2 -AR regulation of sodium absorption in DT cells during developing and established hypertension. As depicted in Figure 1 , the selective ␣ 1 -AR agonist PHE significantly increases sodium uptake into DT cells during developing hypertension in SHR but has no effect in age-matched WKY. By comparison, an ␣ 2 -AR agonist increases sodium uptake in WKY, but not SHR, DT cells. At 12 weeks, both SHR and WKY increase sodium uptake in response to ␣ 2 -but not ␣ 1 -AR agonists. The increased uptake of sodium in SHR DT cells during developing hypertension coincides with high levels of the ␣ 1B -AR subtype protein expressed at this phase ( Figure 4 ). Once hypertension is established, the density of the ␣ 1B -ARs in SHR DT cells is similar to that observed in WKY. Finally, the signaling through increased [Ca 2ϩ ] i also correlates with enhanced ␣ 1B -AR expression and sodium uptake during this phase. Once expression of the ␣ 1B -ARs is reduced during established hypertension, ␣ 1 -AR subtypes no longer signal increases in [Ca 2ϩ ] i in DT cells. Although speculative, ␣ 2 -ARs may regulate final changes in sodium absorption through activation and signaling of the PI-PLC pathway in DT cells. Because this pathway is present in 6-week WKY rats and these animals do not exhibit increased blood pressure, the ␣ 2 -ARs may modulate physiological changes in sodium absorption.
Although the exact mechanisms underlying the upregulation of renal ␣-ARs in SHR remain unclear, the increased density may represent a genetic abnormality. 37 Two lines of evidence support this theory: (1) increased receptor density in SHR occurs before onset of the development of hypertension, and (2) nongenetic models of hypertension do not exhibit increased receptor expression. Several studies show that renal ␣ 2 -AR receptor density is increased in hypertension. [37] [38] [39] Sanchez et al 40 suggests that ␣ 1 -ARs increase during the developing hypertension but that ␣ 2 -ARs density is greater during established hypertension. The data in Figure 4 are consistent with reports that ␣ 1 -ARs increase during developing hypertension. By comparison, our data do not indicate upregulation of ␣ 2 -ARs during developing or established hypertension. Intengan and Smyth 41 suggest a defective modulation of solute excretion in 8-week SHR due to the ␣ 2A/D -AR. This defect is not present in acquired models of hypertension. Our results would be consistent with these observations because ␣ 2 -ARs in DT cells do not signal an increase in [Ca 2ϩ ] i during developing hypertension. During established hypertension and in normotensive animals, the subtype of ␣ 2 -ARs that modulates sodium transport possesses the ability to signal through PI-PLC pathways. 24 Altered renal sodium balance in SHR may represent a consequence of en-hanced ␣ 1 -AR-stimulated retention and lack of ␣ 2 -AR-induced clearance during the developing phase of hypertension.
In summary, we demonstrate that ␣-ARs stimulate sodium uptake in DT cells. During developing hypertension in SHR, the expression of ␣ 1B -AR protein correlates with a significant increase in sodium uptake from ␣ 1 -AR stimulation. In agematched normotensive WKY DT cells, ␣ 2 -ARs are capable of increasing sodium uptake. During established hypertension, the expression of ␣ 1B -ARs is reduced and ␣ 1 -ARs no longer stimulate sodium uptake. In DT cells from SHR with established hypertension and normotensive WKY rats, regulation of sodium transport is mediated by ␣ 2 -ARs. Transient increases in [Ca 2ϩ ] i occur with ␣ 1 -ARs during developing hypertension but switch to ␣ 2 -ARs during established hypertension. The switch in receptor expression and signaling does not occur in PT cells. We propose that the enhancement of ␣ 1 -AR expression that occurs during developing hypertension contributes to the initiation of hypertension, whereas during established hypertension or in normotensive animals, ␣ 2 -ARs modulate sodium transport in DT cells.
